Delisting risk
PPCB · NASDAQ · Biotechnology

Propanc Biopharma (PPCB)

Preclinical developer of proenzyme therapies for solid tumors.

$1.04
Pre-market+0.02 (+1.46%)
At close$1.03(−9.29%)

Breakdown13F · 13D/G · Form 4

2.28M company shares as of Sep 3, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Oasis Capital, LLCStrategic
9.99% of class, as filed13Gfiled Jul 7, 2020
Sylva International LLCStrategic
9.25% of class, as filed13Gfiled Sep 8, 2021
Julian Norman Kenyon1Insiderdirector, officer: Chief Scientific Officer
0.00%0Form 4filed Aug 20, 2021
James Andrew Nathanielsz1Insiderdirector, officer: CEO/CFO
0.00%0Form 4filed Aug 20, 2021
Josef Zelinger1,2Insiderdirector
0.00%0Form 4filed Aug 20, 2021
  1. Last filed Aug 20, 2021; leaving the company requires no filing. Not in the bar.
  2. Josef Zelinger reports a block also reported by James Andrew Nathanielsz; it is counted once, under James Andrew Nathanielsz.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

No 13D/G filer at 5% or more on record.

Insider tradesForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.